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This International Myeloma Working Group consensus updates the disease deﬁ nition of multiple myeloma to include 
validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal 
failure, anaemia, and bone lesions). These changes are based on the identiﬁ cation of biomarkers associated with near 
inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering 
multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be 
detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and 
radiographic variables that fulﬁ l the criteria for the presence of myeloma-deﬁ ning CRAB features, and the histological 
and monoclonal protein requirements for the disease diagnosis. Finally, we provide speciﬁ c metrics that new 
biomarkers should meet for inclusion in the disease deﬁ nition. The International Myeloma Working Group 
recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends 
that future studies analyse any diﬀ erences in outcome that might occur as a result of the new disease deﬁ nition.
Introduction
Multiple myeloma is a cytogenetically heterogeneous 
clonal plasma cell proliferative disorder1,2 and is almost 
always preceded by an asymptomatic premalignant stage 
termed monoclonal gammopathy of undetermined 
signiﬁ cance (MGUS).3,4 MGUS is present in roughly 
3–4% of the population over the age of 50 years.5–9 The 
diagnosis of MGUS requires the absence of hyper-
calcaemia, renal failure, anaemia, and bone lesions 
(referred to as CRAB features) that can be attributed to 
the underlying plasma cell disorder (all features must be 
absent; table 1).10–20 About 80% of multiple myeloma 
originates from non-IgM immunoglobulin MGUS (non-
IgM MGUS), and 20% from light-chain immunoglobulin 
MGUS (LC-MGUS). In the event of progression, IgM 
immunoglobulin MGUS (IgM MGUS) usually evolves 
into Waldenström macroglobulinaemia, but in rare 
instances IgM MGUS can progress to multiple myeloma 
(IgM myeloma).18,21–24 The rate of progression of MGUS to 
multiple myeloma is 0·5–1% per year, but the precise 
risk is aﬀ ected by the concentration of the monoclonal 
protein, type of monoclonal protein, serum free light-
chain ratio, bone marrow plasmacytosis, proportion of 
phenotypically clonal plasma cells, and presence of 
immunoparesis.24–29
Smouldering multiple myeloma is an intermediate 
clinical stage between MGUS and multiple myeloma in 
which the risk of progression to malignant disease in the 
ﬁ rst 5 years after diagnosis is much higher, at about 10% 
per year.30 Prognostic models have been proposed to 
predict risk of progression, but lack con cordance and 
need additional studies for veriﬁ cation.31 According to a 
population-based study from Scandinavia, smouldering 
multiple myeloma accounts for about 14% of all patients 
with multiple myeloma.32 As with MGUS, the diagnosis 
needs the absence of CRAB features attributable to the 
clonal plasma cell proliferative disorder, but the 
thresholds for monoclonal protein level and bone-
marrow plasma cell (BMPC) percentage are diﬀ erent. 
Smouldering multiple myeloma is a biologically 
heterogeneous, clinically deﬁ ned entity consisting of a 
subset of patients with biological premalignancy (ie, 
MGUS) and a subset with CRAB-negative malignancy 
(ie, multiple myeloma).33 It includes patients similar to 
those with MGUS, with a very low rate of progression, as 
well as patients who develop clinical symptoms and end-
organ damage within the ﬁ rst 2 years of diagnosis.34,35 
Unfortunately, no single pathological or molecular 
feature can be used to distinguish patients with 
smouldering multiple myeloma who have only clonal 
premalignant plasma cells from those with clonal 
malignant myeloma cells. A biomarker-based deﬁ nition 
that accurately identiﬁ es the subset of patients with 
smouldering multiple myeloma and biological 
malignancy, who are at imminent risk of developing 
CRAB features (and should therefore be considered for 
therapy), is needed.34
Rationale for updating of diagnostic criteria
The present disease deﬁ nitions of smouldering multiple 
myeloma and multiple myeloma were reported by the 
International Myeloma Working Group (IMWG) in 
2003.10 With minor clariﬁ cations,11 these criteria have 
been used in clinical practice as well as in research 
studies and trials in the past decade.36,37 One of the major 
diﬃ  culties in multiple myeloma is that, unlike other 
malignancies, the disease deﬁ nition is clinicopathological; 
it needs overt clinical manifestations of serious end-
organ damage, such as osteolytic bone lesions and renal 
failure, before the diagnosis can be made. This 
conundrum has ensured that patients cannot get early 
therapy to prevent organ damage, and has prevented any 
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attempts at cancer treatment at a stage when it is in its 
most susceptible microenvironment-dependent state. 
These criteria were acceptable in an era of restricted 
treatment options that had substantial toxic eﬀ ects and 
did not show any apparent clinical beneﬁ t from early 
intervention. However, this deﬁ nition can no longer be 
justiﬁ ed because treatment options have greatly 
improved, and data show early intervention in high-risk 
asymptomatic patients can extend survival.38 Moreover, 
advances in laboratory and imaging techniques call for 
an update on the speciﬁ c variables that should be 
regarded as meeting the criteria for CRAB features.39 
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Serum monoclonal protein (non-IgM type) <30 g/L
Clonal bone marrow plasma cells <10%*
Absence of end-organ damage such as hypercalcaemia, renal insuﬃ  ciency, anaemia, and bone lesions 
(CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder
1% per year Multiple myeloma, solitary 
plasmacytoma, immunoglobulin-




Serum IgM monoclonal protein <30 g/L
Bone marrow lymphoplasmacytic inﬁ ltration <10%
No evidence of anaemia, constitutional symptoms, hyperviscosity, lymphadenopathy, 
hepatosplenomegaly, or other end-organ damage that can be attributed to the underlying 
lymphoproliferative disorder
1·5% per year Waldenström 
macroglobulinaemia, 
immunoglobulin-related 





Abnormal FLC ratio (<0·26 or >1·65)
Increased level of the appropriate involved light chain (increased κ FLC in patients with ratio >1·65 and 
increased λ FLC in patients with ratio <0·26)
No immunoglobulin heavy chain expression on immunoﬁ xation
Absence of end-organ damage such as hypercalcaemia, renal insuﬃ  ciency, anaemia, and bone lesions 
(CRAB) or amyloidosis that can be attributed to the plasma cell proliferative disorder
Clonal bone marrow plasma cells <10%
Urinary monoclonal protein <500 mg/24 h
0·3% per year Light chain multiple myeloma, 
immunoglobulin light-chain 
amyloidosis
Solitary plasmacytoma13–16 Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells
Normal bone marrow with no evidence of clonal plasma cells
Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)
Absence of end-organ damage such as hypercalcaemia, renal insuﬃ  ciency, anaemia, or bone lesions 
(CRAB) that can be attributed to a lymphoplasma cell proliferative disorder




with minimal marrow 
involvement†13–16
Biopsy-proven solitary lesion of bone or soft tissue with evidence of clonal plasma cells
Clonal bone marrow plasma cells <10%
Normal skeletal survey and MRI (or CT) of spine and pelvis (except for the primary solitary lesion)
Absence of end-organ damage such as hypercalcaemia, renal insuﬃ  ciency, anaemia, or bone lesions 
(CRAB) that can be attributed to a lymphoplasma cell proliferative disorder
60% (bone) or 20% 




Monoclonal plasma cell proliferative disorder (almost always λ)
Any one of the following three other major criteria: 
Sclerotic bone lesions
Castleman’s disease
Elevated levels of VEGFA§
Any one of the following six minor criteria:
Organomegaly (splenomegaly, hepatomegaly, or lymphadenopathy)
Extravascular volume overload (oedema, pleural eﬀ usion, or ascites)
Endocrinopathy (adrenal, thyroid, pituitary, gonadal, parathyroid, pancreatic)¶ 
Skin changes (hyperpigmentation, hypertrichosis, glomeruloid haemangiomata, plethora, 






Presence of an amyloid-related systemic syndrome (eg, renal, liver, heart, gastrointestinal tract, or 
peripheral nerve involvement)
Positive amyloid staining by Congo red in any tissue (eg, fat aspirate, bone marrow, or organ biopsy)
Evidence that amyloid is light-chain-related established by direct examination of the amyloid using mass 
spectrometry-based proteomic analysis, or immunoelectronmicroscopy, and
Evidence of a monoclonal plasma cell proliferative disorder (serum or urine monoclonal protein, 
abnormal free light-chain ratio, or clonal plasma cells in the bone marrow)
NA Some patients might develop 
multiple myeloma
IgM=immunoglobulin M. AL=immunoglobulin light-chain amyloidosis. AHL=immunoglobulin heavy and light-chain amyloidosis. AH=immunoglobulin heavy chain amyloidosis. FLC=free light chain. *Bone 
marrow can be deferred in patients with low-risk monoclonal gammopathy of undetermined signiﬁ cance (IgG type, monoclonal protein <15 g/L, normal free light-chain ratio) in whom there are no clinical 
features concerning for myeloma. †Solitary plasmacytoma with 10% or more clonal plasma cells is regarded as multiple myeloma. ‡Not every patient meeting these criteria will have POEMS syndrome; the 
features should have a temporal association with each other and no other attributable cause. Anaemia or thrombocytopenia are distinctively unusual in this syndrome unless Castleman’s disease is present. §The 
source data do not define an optimal cutoﬀ  value for considering elevated VEGFA level as a major criterion. We suggest that VEGFA measured in the serum or plasma should be at least three to four times higher 
than the normal reference range for the laboratory that is doing the testing to be regarded as a major criterion. ¶To regard endocrinopathy as a minor criterion, an endocrine disorder other than diabetes or 
hypothyroidism is required because these two disorders are common in the general population. ||Patients with AL amyloidosis who also meet criteria for multiple myeloma are considered to have both diseases. 
**About 2–3% of patients with AL amyloidosis will not meet the requirement for evidence of a monoclonal plasma cell disorder listed; the diagnosis of AL amyloidosis must be made with caution in these 
patients. ††All presented criteria must be met for the disease to be diagnosed.
Table 1: International Myeloma Working Group diagnostic criteria and classiﬁ cation for monoclonal gammopathy of undetermined signiﬁ cance and related plasma-cell disorders
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Finally, some revisions to the monoclonal protein and 
bone marrow plasma cell requirements are also needed.
Myeloma-deﬁ ning biomarkers
To intervene before the development of end-organ 
damage in multiple myeloma, biomarkers are needed 
that accurately identify the subset of patients with 
smouldering multiple myeloma who have biological 
malignancy and are at imminent risk of progression.35,40–44 
A Mayo Clinic study45 of patients with smouldering 
multiple myeloma reported that having a BMPC of at 
least 60% can be used as a marker to identify patients 
with a notably high risk (about 90%) of progression 
within 2 years of diagnosis. In 2011 at a summit in 
London, UK, the IMWG reached a consensus that, if 
reliable biomarkers associated with roughly an 80% 
probability of progression to multiple myeloma within 
2 years were identiﬁ ed, such patients should be regarded 
as having multiple myeloma and oﬀ ered therapy. This 
threshold would identify a small cohort of smouldering 
multiple myeloma with a median time to development of 
end-organ damage of about 12 months, for whom a delay 
of therapy would be unreasonable. The IMWG consensus 
was driven by the following considerations. First, this 
very high-risk cohort is not representative of most 
patients with smouldering multiple myeloma, in view of 
the 40% per year risk of progression (based on the 
prespeciﬁ ed deﬁ nition), compared with the 10% per year 
risk of progression with smouldering multiple myeloma. 
Second, one of the reasons to delay therapy in 
smouldering multiple myeloma is based on the fact that 
a substantial proportion of patients can remain free of 
progression for long periods of time. For example, 50% 
of patients with smouldering multiple myeloma do not 
progress in the ﬁ rst 5 years, and roughly 30% are free of 
progression after 10 years.30 Such con siderations do not 
apply to this ultra-high risk subgroup in which few, if 
any, patients are free of progression beyond 3 years. 
Third, the proportion of patients who do not progress 
within 2 years (up to 20%) was regarded to be reasonable, 
because these patients are probably not very diﬀ erent 
from some patients with multiple myeloma who have 
minimal CRAB features for whom prompt treatment is 
widely accepted (eg, patients with one or two lytic lesions, 
or mild anaemia), yet who can remain stable without 
therapy. Fourth, the results of end-organ damage, 
especially acute renal failure or pathological fracture, 
were judged to be unacceptably severe, with risk of 
substantial long-term morbidity. Therefore, we believed 
that persisting with a disease deﬁ nition that demanded 
such damage occur before the disease is called multiple 
myeloma was unreasonable for patients. Finally, we 
believed that major advances have been made in the 
treatment of multiple myeloma, and although watchful 
waiting was appropriate in an era of only alkylating 
agents and corticosteroids, it was not justiﬁ able for ultra-
high-risk patients in view of the availability of several 
safer and more eﬀ ective treat ments.46–51 Trials with 
alkylators that did not show an increase in overall survival 
with early treatment for smouldering multiple myeloma 
were underpowered, and did not focus on high-risk 
patients.52,53 A randomised trial38 done in 2013 reported 
that early therapy for smouldering multiple myeloma 
can extend overall survival, greatly diminishing concerns 
that treatment of patients with a very high-risk of 
smouldering multiple myeloma as multiple myeloma 
will lead to overtreatment or unnecessary therapy.
Revisions to laboratory and imaging criteria for CRAB
In addition to the previous discussion on incorporation 
of additional biomarker-deﬁ ned myeloma-deﬁ ning 
events to the standard CRAB features, updates are also 
needed that take into account the substantial changes to 
laboratory testing and imaging used in the diagnosis of 
multiple myeloma that have happened since the initial 
publication of the IMWG diagnostic criteria. These 
include better methods of detecting bone and 
extramedullary disease using CT (including low-dose 
whole body CT), MRI, ¹⁸F-ﬂ uorodeoxyglucose (FDG) 
PET, and FDG-PET with CT (PET-CT).54–56 They also 
include better estimation of renal damage by use of 
creatinine clearance in addition to serum creatinine 
measurements, and the criteria for clonal bone marrow 
plasma cells needed on bone marrow examination have 
been revised.
Other revisions
Other minor clariﬁ cations to the disease deﬁ nition are 
needed to account for patients with non-secretory 
multiple myeloma (where there is no monoclonal protein 
in any tests), and patients with normal or scarcely 
involved (<10% clonal plasma cells) bone marrow 
examinations who have multiple lytic lesions, plasma-
cytomas (bony or extramedullary), or other CRAB 
features without diﬀ use inﬁ ltration of the marrow.
Revised IMWG criteria for diagnosis of myeloma
The updated IMWG criteria for diagnosis of multiple 
myeloma are given in the panel; the supporting data for 
each of the changes are discussed below. The term 
multiple myeloma refers to multiple myeloma requiring 
therapy.
Bone marrow plasma cells of 60% or greater
In 2011, a re-analysis of the original Mayo Clinic cohort of 
smouldering multiple myeloma noted that only six (2%) 
of 276 patients had a BMPC of 60% or greater (deﬁ ned as 
the highest percentage noted on an aspirate or trephine 
biopsy sections). The median progression-free survival 
was 7·7 months (95% CI 0·4–14·9), and ﬁ ve of the six 
patients (83%) patients had progressed or died by 
14 months.45
To validate this ﬁ nding, a study was done in a new 
group of 651 patients with smouldering multiple 
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myeloma diagnosed at the Mayo Clinic between 
January, 1996, and June, 2010.45 Only 21 (3%) patients 
had a BMPC of 60% or greater, and 95% of these 
patients progressed to multiple myeloma within 2 years 
of diagnosis (median time to progression 7·0 months 
[95% CI 1·0–12·9]). These studies showed that extreme 
plasmacytosis was uncommon in smouldering multiple 
myeloma, because at that level of plasmacytosis, CRAB 
features—especially anaemia—almost always occur, 
which results in a diagnosis of multiple myeloma. The 
investigators recommended that in view of the clinical 
course noted, patients with 60% or greater plasma cell 
involvement on marrow examination should be 
regarded as having multiple myeloma requiring therapy 
irrespective of the presence or absence of CRAB 
features. This ﬁ nding was subsequently validated in an 
investi gation of 96 patients with smouldering multiple 
myeloma by Kastritis and colleagues from the Greek 
Myeloma Group, who showed that BMPC of 60% of 
greater was associated with a high risk of progression 
(median time to progression of 15·0 months, hazard 
ratio [HR] 13·7 [95% CI 4·44–42·50]; p<0·001).57 Six 
(5%) of 121 patients with smouldering multiple 
myeloma in a third study were reported to have BMPC 
60% or greater, and all progressed to multiple myeloma 
within 2 years.58
BMPC estimation for diagnosis is based on either 
conventional bone marrow aspirate or biopsy 
examination. BMPC estimation should not be based on 
the proportion of plasma cells reported by ﬂ ow cytometry; 
studies are ongoing to determine whether ﬂ ow-based 
enumeration is feasible.59 If a discrepancy exists between 
BMPC estimation in the biopsy sample and aspirate, the 
higher of the two values should be used.60
Serum free light chain ratio of 100 or greater
The free light chain (FLC) assay is an automated 
nephelometric assay that identiﬁ es and measures κ and λ 
light immunoglobulin chains that circulate unbound to 
heavy chains in the serum.61–63 The normal ratio for FLC-
κ/λ is 0·26–1·65. In clonal plasma cell disorders, excess 
production of one FLC type (the clonal component 
referred to as the involved light chain) often results in an 
abnormal FLC ratio.64 About a third of patients with 
MGUS, 70% of patients with smouldering multiple 
myeloma, and more than 90% of patients with multiple 
myeloma have altered FLC ratios that indicate excess 
production of a clonal FLC by the proliferating plasma 
cell population.27,44,65,66 The presence of an abnormal FLC 
ratio, and the extent to which the FLC ratio is abnormal, 
predict risk of progression in MGUS, smouldering 
multiple myeloma, amyloid light-chain (AL) amyloidosis, 
and solitary plasmacytoma.27,44,67
Dispenzieri and colleagues44 reported that in patients 
with smouldering multiple myeloma, an involved to 
uninvolved FLC ratio of 8 or more is associated with 
about a 40% risk of progression within the ﬁ rst 2 years 
from diagnosis. Subsequently, Larsen and colleagues68 
studied 586 patients with smouldering multiple myeloma 
to determine the threshold at which the FLC ratio is 
associated with an 80% probability of progression to 
multiple myeloma or related malignant disease within 
2 years. A serum involved to uninvolved FLC ratio of at 
least 100 was noted in 90 (15%) patients of the total 
cohort; the involved FLC level was higher than the 
normal range in all. The risk of progression to multiple 
myeloma within the ﬁ rst 2 years in patients with an FLC 
ratio of at least 100 was 72%; the risk of progression to 
multiple myeloma or AL amyloidosis in 2 years was 79%. 
The risk of progression to multiple myeloma or AL 
amyloidosis for patients with an FLC ratio of at least 100 
and an involved FLC level at least 1000 mg/L was 82% at 
2 years, and 93% at 3 years. Taking an absolute FLC level 
threshold into account improved positive predictive value 
of the FLC assay, but lowered sensitivity. Importantly, 
27% of patients with a FLC ratio of at least 100 had acute 
renal failure as the myeloma-deﬁ ning event. The 
researchers concluded that a FLC ratio of at least 100 is a 
predictor of imminent progression in smouldering 
Panel: Revised International Myeloma Working Group diagnostic criteria for multiple 
myeloma and smouldering multiple myeloma
Deﬁ nition of multiple myeloma
Clonal bone marrow plasma cells ≥10% or biopsy-proven bony or extramedullary 
plasmacytoma* and any one or more of the following myeloma deﬁ ning events:
• Myeloma deﬁ ning events: 
• Evidence of end organ damage that can be attributed to the underlying plasma cell 
proliferative disorder, speciﬁ cally:
• Hypercalcaemia: serum calcium >0·25 mmol/L (>1 mg/dL) higher than the 
upper limit of normal or >2·75 mmol/L (>11 mg/dL)
• Renal insuﬃ  ciency: creatinine clearance <40 mL per min† or serum creatinine 
>177 μmol/L (>2 mg/dL)
• Anaemia: haemoglobin value of >20 g/L below the lower limit of normal, or a 
haemoglobin value <100 g/L
• Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or 
PET-CT‡
•  Any one or more of the following biomarkers of malignancy:
• Clonal bone marrow plasma cell percentage* ≥60%
• Involved:uninvolved serum free light chain ratio§ ≥100
• >1 focal lesions on MRI studies¶
Deﬁ nition of smouldering multiple myeloma
Both criteria must be met:
• Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 mg 
per 24 h and/or clonal bone marrow plasma cells 10–60%
• Absence of myeloma deﬁ ning events or amyloidosis
PET-CT=¹⁸F-ﬂ uorodeoxyglucose PET with CT. *Clonality should be established by showing κ/λ-light-chain restriction on ﬂ ow 
cytometry, immunohistochemistry, or immunoﬂ uorescence. Bone marrow plasma cell percentage should preferably be 
estimated from a core biopsy specimen; in case of a disparity between the aspirate and core biopsy, the highest value should be 
used. †Measured or estimated by validated equations. ‡If bone marrow has less than 10% clonal plasma cells, more than one 
bone lesion is required to distinguish from solitary plasmacytoma with minimal marrow involvement. §These values are based 
on the serum Freelite assay (The Binding Site Group, Birmingham, UK). The involved free light chain must be ≥100 mg/L. ¶Each 
focal lesion must be 5 mm or more in size. 
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multiple myeloma, and that such patients should be 
regarded as having multiple myeloma requiring therapy.
Similar results were obtained in work by Kastritis and 
colleagues57 from the Greek Myeloma Group. In their 
investigation of 96 patients with smouldering multiple 
myeloma, seven (7%) had an involved to uninvolved 
FLC ratio of at least 100, and almost all progressed 
within 18 months (HR 9·0 [95% CI 2·15–39·00], 
p=0·003). In a third study,58 the risk of patients with 
smouldering multiple myeloma with an involved to 
uninvolved FLC ratio of at least 100 progressing within 
2 years was 64%. Although these studies did not need a 
minimum involved FLC level, to reduce possibility of 
error the new criteria require a minimum involved FLC 
level of at least 100 mg/L.
MRI with more than one focal lesion
MRI is beneﬁ cial in evaluating patients with smouldering 
multiple myeloma, and is recommended as part of the 
initial assessment.54 Abnormal MRI imaging features in 
smouldering multiple myeloma include both focal 
lesions (involving bone or bone marrow), and diﬀ use 
bone marrow abnormalities. These abnormalities have 
been associated with increased risk of progression in 
smouldering multiple myeloma.69–71 However, only within 
the past 5 years have investigators precisely determined 
the level of abnormality that is associated with a high 
probability of progression within 2 years. Hillengass and 
colleagues72 studied 149 patients with smouldering 
multiple myeloma with whole-body MRI. Focal lesions 
were detected in 42 (28%) patients; more than one focal 
lesion was identiﬁ ed in 23 (15%) patients of the total 
cohort. The presence of more than one focal lesion was 
associated with a substantial increase in risk of 
progression (HR 4·05, p<0·001; univariate analysis). The 
median time to progression was 13 months, and 70% of 
patients had progressed at 2 years. On multivariate 
analysis, presence of more than one focal lesion 
remained a signiﬁ cant predictor of progression. In 
patients with more than one focal lesion on MRI, if such 
lesions are small (<5 mm) or equivocal, additional 
imaging with CT or PET-CT should be considered before 
making the diagnosis of multiple myeloma.
Kastritis and colleagues73 analysed data from the Greek 
Myeloma Database and identiﬁ ed 65 patients with 
smouldering multiple myeloma who underwent spinal 
MRI and were followed up for a minimum of 2·5 years. 
In this cohort, nine (14%) patients had more than one 
focal lesion. The median time to progression to multiple 
myeloma for patients with more than one focal lesion 
was 15 months (95% CI 6–26). At 2 years, 69% of patients 
had progressed, as had 85% at 3 years. By contrast, the 
median time to progression for patients with one or no 
focal lesions was over 5 years (p<0·001).
A diﬀ use marrow inﬁ ltration pattern is associated with 
an increased risk of progression, but is not recommended 
as adequate to establish the diagnosis of multiple 
myeloma. Additional data are needed on the speciﬁ c risk 
of progression in the ﬁ rst 2 years in the absence of focal 
lesions and extreme bone marrow plasmacytosis.74,75 In 
the study by Hillengass,72 diﬀ use MRI inﬁ ltration was 
associated with a HR of 3·5 (p<0·001). A 2014 analysis76 
shows that the increase in number or size of focal lesions 
in follow-up MRI of patients with smouldering multiple 
myeloma has additional predictive value, including 
information on growth dynamics of the plasma cell 
tumours in bone marrow. Therefore, in patients with 
diﬀ use inﬁ ltration, solitary focal lesion, or in the presence 
of equivocal ﬁ ndings, follow-up examinations in 
3–6 months are strongly recommended.
Deﬁ nition of myeloma bone disease
Bone disease in multiple myeloma, to meet the CRAB 
criteria, has been deﬁ ned as the presence of osteolytic 
bone lesions or the presence of osteoporosis with 
compression fractures attributable to the underlying 
clonal plasma cell disorder.10,11 Traditionally, bone disease 
has been identiﬁ ed on the basis of conventional skeletal 
radiography. The 2003 IMWG criteria for the diagnosis 
of multiple myeloma concluded that MRI and CT can be 
used to clarify the presence of bone disease.10 Although 
the criteria did not explicitly state that these modalities 
can be used in isolation to fulﬁ l the CRAB criteria in the 
absence of bone disease on skeletal radiography, it was 
the intent of the investigators that a deﬁ nite osteolytic 
lesion detected on CT should be regarded as fulﬁ lling 
CRAB criteria even if it was not visible on conventional 
skeletal radiography (RAK, unpublished data). In the 
past 10 years substantial advances have been made in 
imaging technology, as well as more widespread use of 
MRI, low-dose whole-body CT, and FDG-PET to assess 
bone disease and bone marrow inﬁ ltration in multiple 
myeloma.54,55,77–81 A 2013 systematic review56 compared 
modern imaging methods including MRI, FDG-PET, 
PET-CT, and whole-body CT with conventional whole-
body skeletal radiography. Newer imaging techniques 
had greater sensitivity than radiographic bone survey for 
detection of multiple myeloma bone lesions, with as 
many as 80% or more lesions detected by the newer 
imaging techniques. CT and MRI were equally sensitive, 
and thus either test can be used, depending on availability 
and access. Furthermore, the IMWG recommended the 
use of these techniques during the diagnostic assessment 
of patients with smouldering multiple myeloma and 
solitary plasmacytoma.21 The IMWG recommends that 
one of PET-CT, low-dose whole-body CT, or MRI of the 
whole-body or spine be done in all patients with 
suspected smouldering multiple myeloma, with the exact 
imaging modality determined by availability and 
resources.
In this updated IMWG criteria, we now clarify that 
clear evidence of one or more sites of osteolytic bone 
destruction (≥5 mm in size) seen on CT (including low-
dose whole-body CT) or PET-CT does fulﬁ l the criteria for 
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bone disease in multiple myeloma, and should be 
regarded as meeting the CRAB requirement irrespective 
of whether they can be visualised on skeletal radiography 
or not. Increased uptake on PET-CT alone is not adequate 
for the diagnosis of multiple myeloma; evidence of 
underlying osteolytic bone destruction is needed on the 
CT portion of the examination. Among 13 patients at the 
Mayo Clinic with suspected smouldering multiple 
myeloma and one or more osteolytic lesions on PET-CT 
who were observed without therapy, ten progressed 
within 2 years (SVR, unpublished data). Care should be 
taken to avoid over-interpretation of equivocal or tiny 
lucencies seen only on CT or PET-CT; as with skeletal 
surveys, if there are doubts about the nature of these 
lesions, a repeat study in 3–6 months should be done 
before a diagnosis of multiple myeloma is made. Such 
patients might be followed up closely at 1–3 month 
intervals before systemic therapy is started. Similarly, 
patients could have other concurrent malignancies with 
associated bone metastases. When the diagnosis is in 
doubt, a biopsy of one of the bone lesions should be 
considered. Furthermore, in view of the incorporation 
and availability of more sensitive imaging modalities to 
identify osteolytic bone destruction, we no longer 
recommend the presence of osteoporosis or vertebral 
compression fractures alone in the absence of lytic 
lesions as being suﬃ  cient evidence of bone disease for 
purposes of the diagnostic criteria. However, if vertebral 
compression fractures are seen in younger patients with 
monoclonal gammopathy, judgment should be exercised, 
and additional imaging such as CT or PET-CT should be 
done to clarify that the changes are not related to 
myeloma. Bone densitometry studies are not suﬃ  cient to 
determine presence of multiple myeloma bone disease. 
Overdiagnosis of multiple myeloma among elderly 
patients with MGUS would be highly likely if osteoporosis 
and compression fractures alone were regarded as 
suﬃ  cient for CRAB features.
When only one osteolytic bone lesion is seen in the 
presence of 10% or more clonal plasma cells, no clear 
indication is present for systemic therapy if no other 
criteria are met for active myeloma, and further thought 
is needed. This circumstance is rare, and we recommend 
that patients could be given radiation therapy and 
observed. Clinical trials to determine the value of adjuvant 
systemic therapy for these patients are being planned.
Deﬁ nition of renal failure
Renal insuﬃ  ciency is deﬁ ned in the 2003 IMWG criteria 
as a serum creatinine concentration of more than 
173 μmol/L (roughly >2 mg/dL) that is attributable to 
multiple myeloma; this value corresponds to an increase 
of 40% above the normal upper limit of the serum 
creatinine.10 However, use of a ﬁ xed concentration of 
serum creatinine to deﬁ ne renal insuﬃ  ciency results in 
patients needing widely diﬀ erent levels of renal 
dysfunction, based on age, sex, and race, to fulﬁ l the 
diagnostic criteria for multiple myeloma. For example, a 
serum creatinine concentration of 173 μmol/L in an 
individual weighing 70 kg corresponds to glomerular 
ﬁ ltration rates of 38 mL/min in a 40-year-old man, 
28 mL/min in a 40-year-old woman, 35 mL/min in a 
65-year-old man, and 26 mL/min in a 65-year-old woman. 
This drawback is well-recognised, and has already been 
addressed in most modern clinical trials, in which 
creatinine clearance (estimated glomerular ﬁ ltration 
rates) is used for eligibility criteria. The IMWG therefore 
recommends that measured or estimated glomerular 
ﬁ ltration rates (according to the modiﬁ cation of diet in 
renal disease [MDRD] or chronic kidney disease 
epidemiology collaboration [CKD-EPI] formulae) less 
than 40 mL/min (which corresponds to about a 40% 
decrease from the lower limit of the normal glomerular 
ﬁ ltration rates) be used instead of a ﬁ xed serum creatinine 
concentration to fulﬁ l the CRAB criteria. This ensures 
that a similar level of renal dysfunction attributable to the 
underlying plasma cell disorder is used to deﬁ ne the 
disease.
The criteria have also been updated to clarify that only 
renal failure caused by light-chain cast nephropathy (based 
on typical histological changes or presumptive diagnosis 
based on the presence of high involved FLC levels, typically 
>1500 mg/L) is regarded as a myeloma-deﬁ ning events. 
Although other forms of renal damage (eg, AL amyloidosis, 
monoclonal immunoglobulin deposition disease, light-
chain Fanconi syndrome, monoclonal gammopathy-
associated mem bra no proliferative glomerulo nephritis) can 
occur in multiple myeloma, this asso ciation is not 
characteristic of multiple myeloma  and can be seen with 
other types of plasma cell dyscrasias (eg, MGUS) or 
lymphoproliferative disorders. Although they can occur in 
conjunction with multiple myeloma, in most patients they 
occur independently without evidence of other myeloma-
deﬁ ning events. For this reason, these renal disorders are 
not regarded as myeloma-deﬁ ning events, and should not 
lead to multiple myeloma diagnosis, unless they meet 
criteria for multiple myeloma as listed in the panel. These 
entities represent unique disease states with clearly deﬁ ned 
pathological features, diagnostic criteria, prognosis, and 
therapy. Some investigators have collectively referred to 
these disorders under the term monoclonal gammopathy 
of renal signiﬁ cance.82 Other causes of acute and chronic 
renal failure (eg, diabetic nephropathy, nephrotoxic drugs, 
pre-renal failure) should be carefully excluded. We 
recommend a renal biopsy to clarify the underlying cause 
of the renal failure in patients with suspected cast 
nephropathy, especially if the serum involved FLC levels 
are less than 500 mg/L, which is also consistent with the 
recommendations of the International Kidney and 
Monoclonal Gammopathy Research Group.83
Monoclonal protein requirements
The 2003 IMWG criteria recognised that serum or urinary 
monoclonal protein is not present in all patients with 
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multiple myeloma, and that a distinct subset of patients 
with non-secretory multiple myeloma exist (representing 
about 3% of multiple myeloma) who have no detectable 
abnormalities on serum or urine immunoﬁ xation.10 
Roughly 30% of such patients also have a normal serum 
FLC assay.84 Because these patients clearly have multiple 
myeloma by virtue of meeting other required criteria, and 
since the clonal nature of the plasma cell proliferation is 
established on histopathology, the requirement for 
monoclonal protein presence  as part of the diagnostic 
criteria is not mandatory. Instead, the presence or absence 
of an monoclonal protein is used to subdivide multiple 
myeloma into secretory and non-secretory types.
Bone marrow plasma cell requirements
A bone marrow examination showing presence of clonal 
plasma cells or histopathological evidence of a 
plasmacytoma is a deﬁ nite requirement for the diagnosis 
of multiple myeloma. In the 2003 IMWG criteria,10 the 
minimum percentage of BMPC needed for the diagnosis 
of multiple myeloma was not stated. Only 3–5% of 
multiple myeloma is associated with BMPC of less than 
10%.85 The revised diagnostic criteria clarify that in these 
patients, the diagnosis of multiple myeloma needs a 
repeat bone marrow biopsy showing 10% or more clonal 
plasma cells, or an image-guided (CT or MRI) biopsy of a 
bony or extramedullary lesion (plasmacytoma).85 In some 
of these patients this trait is caused by sampling error or 
patchy bone marrow involvement, while in the others 
there are multiple plasmacytomas or lytic lesions with no 
generalised marrow involvement (macrofocal multiple 
myeloma).86 CRAB features cannot be regarded as being 
attributable to clonal plasma cell proliferation if BMPC is 
less than 10% and there is no biopsy-proven plasma-
cytoma. Patients with related plasma cell proliferative 
disorders such as AL amyloidosis, POEMS syndrome, or 
monoclonal gammopathy-associated proliferative 
glomerulo nephritis might seem to have CRAB-like 
features despite low levels of bone-marrow plasma-
cytosis.82,87,88 In these instances, the patient should not be 
deﬁ ned as having concomitant multiple myeloma unless 
they meet the criteria listed in the panel. Based on these 
considerations, and to prevent patients with MGUS from 
being wrongly classiﬁ ed as multiple myeloma based on 
unrelated features of anaemia, hypercalcaemia, or renal 
dysfunction, the criteria have been updated to clarify that 
either clonal BMPC of 10% or more, or a biopsy-proven 
plasmacytoma, is needed for the diagnosis of multiple 
myeloma. Some patients who are suspected of having 
multiple myeloma with clonal BMPC of less than 10% 
might have lytic lesions or plasmacytomas that are 
inaccessible for biopsy; judgment should be used in the 
care of these patients, and additional bone marrow 
examinations or follow-up testing might be needed to 
clarify the diagnosis. Finally, patients with solitary 
plasmacytoma meeting criteria described in table 1 
should not be regarded as having multiple myeloma.
The estimate of bone marrow plasmacytosis should be 
determined by conventional bone marrow aspirate or 
biopsy examination. If there is a discrepancy, the higher of 
the two values should be used.60 Clonality of bone marrow 
plasma cells should be established by demon stration of 
κ/λ light-chain restriction by immuno histochemistry or 
immuno ﬂ uorescence, or by demonstration of phenotypic 
clonality by ﬂ ow cytometry, or by immunoglobulin gene 
rearrangement studies.
Clariﬁ cation of the need for symptoms
CRAB features are typically associated with symptoms. 
However, we clarify that the term symptomatic is used to 
refer to patients with presence of CRAB features 
attributable to the underlying clonal plasma cell disorder, 
even if they are not symptomatic to the patient, but rather 
discovered during tests. This clariﬁ cation is mainly to 
help in interpretation of existing trials. Since the updated 
criteria include other asymptomatic patient subgroups, 
this is of less importance now. The term multiple 
myeloma is preferred instead of the term symptomatic 
multiple myeloma.
Other related organ or tissue impairment
Although the 2003 IMWG criteria included non-CRAB 
end-organ damage, speciﬁ cally hyperviscosity, AL 
amyloidosis, and recurrent bacterial infections as 
fulﬁ lling criteria for multiple myeloma, over the years 
only CRAB features have been regarded as myeloma-
deﬁ ning events.10,11 Hyperviscosity is seen mainly with 
high immunoglobulin A (IgA) levels (usually >30 g/L but 
varies between patients); such levels are almost never 
seen without other CRAB features, especially anaemia, 
as a substantial tumour load is needed to produce this 
event. Systemic AL amyloidosis is a distinct plasma cell 
dyscrasia, and its presence in a patient with a monoclonal 
gammopathy does not automatically suggest multiple 
myeloma. There are studies89 that try to deﬁ ne the 
speciﬁ c myeloma-deﬁ ning event needed for the diagnosis 
of concurrent multiple myeloma in patients with AL 
amyloidosis. Recurrent infection is a nonspeciﬁ c 
criterion, and in view of the prevalence of MGUS in the 
elderly general population, it is not thought of as a 
validated or reliable myeloma-deﬁ ning event in the 
absence of other CRAB features. Finally, all of these have 
also become less important with the inclusion of new 
non-CRAB biomarkers to deﬁ ne the disease. Thus, we do 
not recommend their use for the initiation of treatment.
Peripheral neuropathy is often seen in association with 
monoclonal gammopathies, and in some cases is causally 
related to the underlying monoclonal immunoglobulin. 
The pathogenesis is thought to be related to the eﬀ ect of 
the monoclonal protein (or secondary biological 
mechanisms) on the peripheral nerves, and can occur in 
patients with MGUS without need for malignant 
transformation.90 Thus, peripheral neuropathy alone is 
not a myeloma-deﬁ ning event, and patients in whom a 
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causal role of the monoclonal protein is suspected are 
regarded as having monoclonal gammopathy-associated 
neuropathy.
All CRAB features used for diagnosis must be 
attributable to the underlying plasma cell disorder. In 
particular, hypercalcaemia in the absence of clear multiple 
myeloma bone disease must be carefully investigated to 
rule out other causes such as hyperparathyroidism. 
Similarly, care should be taken in attribution of clinically 
signiﬁ cant anaemia as a CRAB criterion for multiple 
myeloma if the extent of BMPC involvement seems 
negligible relative to the degree of reduction in 
haemoglobin or haematocrit.
Other speciﬁ c disease states
The present IMWG diagnostic criteria and recommended 
terminology for MGUS and related plasma cell disorders, 
including solitary plasmacytoma and immunoglobulin 
light-chain amyloidosis, are listed in table 1. The 
prognosis of solitary plasmacytoma varies depending on 
presence of clonal plasma cells in the bone marrow.12–16 It 
therefore consists of two distinct entities: solitary plasma-
cytoma (no clonal BMPCs) and solitary plasmacytoma 
with low marrow involvement (<10% clonal BMPCs). By 
contrast, patients with solitary plasmacytoma and 10% or 
more of clonal plasma cells are classiﬁ ed as multiple 
myeloma. The IMWG also recommends that POEMS 
syndrome91 and osteosclerotic multiple myeloma92 be 
regarded as distinct subtypes of multiple myeloma, given 
the markedly diﬀ erent clinical presentation, therapeutic 
approach, response to treatment, and prognosis.
Future directions
The updated diagnostic criteria move multiple myeloma 
into line with other malignancies by removing the need 
for documented end-organ damage as a mandatory 
requirement for the deﬁ nition of malignancy.34,35,39–42,57 
They address a major drawback in terminology that 
prevented patients with clearcut malignancy and very 
high risk of developing end-organ damage from receiving 
therapy until such damage is clinically manifest.
Promising markers for further study are listed in 
table 2.93–99 Multiparametric ﬂ ow cytometry can help 
distinguish clonal from normal plasma cells. In patients 
with MGUS, a substantial proportion of polyclonal 
plasma cells persist, whereas in multiple myeloma 
almost all plasma cells (>95%) are clonal.28,94,95 Patients 
with smouldering multiple myeloma who display an 
immunophenotypic pattern identical to multiple 
myeloma have a higher risk of progression.38 High levels 
of circulating plasma cells and high proliferative rate of 
bone marrow plasma cells can accurately identify 
patients with ultra-high risk of progression, but the 
methods that have been reported are not universally 
available, and cut-oﬀ  points using sensitive and 
automated multiparametric ﬂ ow cytometric methods are 
needed.93,99 Speciﬁ c cytogenetic abnormalities, especially 
translocation t(4;14), 1q gain, and deletion 17p, have been 
associated with a high risk of progression in smouldering 
multiple myeloma and need to be combined with other 
known biomarkers to improve predictive value.97,98 In 
future, genomic markers will probably be incorporated 
to more accurately predict risk of progression.100
An increase in the serum monoclonal protein level by 
at least 10% on two successive evaluations within a 
6-month period has been associated with a 65% 
probability of progression in smouldering multiple 
myeloma.96 However, in the observation group of the 
Spanish trial of smouldering multiple myeloma,38 
patients with a rise in monoclonal protein of at least 25% 
over two successive evaluations did not have a signiﬁ cant 
increase in risk of progression compared with patients 
without such an increase (2-year risk of 69% with 
increased monoclonal protein vs 75% for controls; MMV, 
unpublished data). Even increasing the threshold to a 
50% or 100% increase did not result in signiﬁ cant 
diﬀ erences. However, the Spanish trial included only 
high-risk smouldering multiple myeloma, and more data 
are needed.96 At present, data are insuﬃ  cient to 
incorporate increasing monoclonal protein as a myeloma-
deﬁ ning event; we recommend that such patients be 
followed up more closely, and advanced imaging 
methods be considered to determine whether they meet 
the present diagnostic criteria for multiple myeloma.
Additional biomarkers with the same or better 
performance characteristics than the ones included in 
this updated deﬁ nition will probably be identiﬁ ed with 
2-year probability of progression
High levels of circulating plasma cells 80%93
Abnormal plasma cell immunophenotype ≥95% plus immunoparesis 50%28,38,94,95
Evolution of smouldering multiple myeloma* 65%96
Cytogenetic subtypes: t (4;14), 1q amp, or del 17p 50%97,98
High bone marrow plasma cell proliferative rate 80%99
Unexplained decrease in creatinine clearance by ≥25% accompanied by a 
rise in urinary monoclonal protein or serum free light-chain 
concentrations
Not known
*Increase in serum monoclonal protein by ≥10% on each of two successive evaluations within a 6-month period.
Table 2: Potential future biomarkers for diagnosis of multiple myeloma
Search strategy and selection criteria
We searched PubMed for articles published in English 
between Jan 1, 1980, and June 30, 2014, that contained the 
term “smoldering myeloma” and any one of the following 
terms: “prognosis” or “imaging” or “biomarkers” or “risk 
factors” or “progression” or “therapy”. We also reviewed 
recent reviews on smouldering multiple myeloma. Members 
of the International Myeloma Working Group were then 
asked to identify any appropriate citation that was of interest 
but not detected by the search strategy.
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ongoing research. The IMWG recognises that validated 
(ie, substantiated by more than two independent studies) 
biomarkers associated with a risk of progression of 
smouldering multiple myeloma to multiple myeloma of 
at least 80% within 2 years can be added to the diagnostic 
criteria in the future.
Contributors
SVR and JSM wrote the ﬁ rst draft of the manuscript after reviewing 
scientiﬁ c literature and discussion with members of the International 
Myeloma Working Group. All authors listed on the manuscript reviewed 
the draft, provided detailed input and comments, and contributed to the 
ﬁ nal report.
Declaration of interests
MAD reports personal fees from Celgene, Ortho Biotech, and Onyx. 
AP reports personal fees from Amgen, Bristol-Myers Squibb, 
Genmab A/S, Janssen-Cilag, Millennium Pharmaceuticals, Onyx 
Pharmaceuticals, Celgene, Sanoﬁ  Aventis, and Array BioPharma. 
JB reports personal fees from Celgene and Janssen. GM reports 
personal fees from Millennium Takeda. SK reports grants from 
Celgene, Millennium, Novartis, Cephalon/Teva, Abbvie, and Onyx. 
PR has been a member of advisory committees for Millennium, 
Celgene, Johnson & Johnson, and Novartis. BP has received honoraria 
from Millennium, Celgene, Janssen, and The Binding Site Group Ltd. 
AD reports grants from Celgene, Millennium, Pﬁ zer, and Jannsen. 
BW reports grants and personal fees from Janssen Research and 
Development, personal fees from Celgene and Onyx, and grants from 
Millennium. SZ reports grants from Celgene, Janssen, and Millennium. 
SL reports personal fees from Millennium, Celgene, Novartis, Onyx, 
Sanoﬁ , Janssen, and Bristol-Myers Squibb. LR has received honoraria 
from Janssen and Celgene. EZ reports grants from Jansen-Cilag and 
Celgene. SJ has been a consultant for Celgene, Sanoﬁ , and Bristol-
Myers Squibb. OS reports personal fees from Celgene and Janssen. 
MB is in the speakers bureau for Celgene, Janssen-Cilag and Amgen, 
and serves on advisory boards for Janssen-Cilag, Bristol-Myers Squibb, 
and Novartis. MC reports personal fees from Janssen, Celgene, 
Millennium, Onyx, and Bristol-Myers Squibb. KCA reports personal 
fees from Celgene, Millennium, Gilead, Sanoﬁ  Aventis, and Onyx. All 
other authors declare no competing interests.
References
1 Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 
364: 1046–60.
2 Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 
2011; 8: 479–91.
3 Landgren O, Kyle RA, Pfeiﬀ er RM, et al. Monoclonal gammopathy 
of undetermined signiﬁ cance (MGUS) consistently precedes 
multiple myeloma: a prospective study. Blood 2009; 113: 5412–17.
4 Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A 
monoclonal gammopathy precedes multiple myeloma in most 
patients. Blood 2009; 113: 5418–22.
5 Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of 
monoclonal gammopathy of undetermined signiﬁ cance. 
N Engl J Med 2006; 354: 1362–69.
6 Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in 
the prevalence of monoclonal gammopathies: a population-based 
study of 12,482 persons from the National Health and Nutritional 
Examination Survey. Leukemia 2014; 28: 1537–42.
7 Bladé J. Monoclonal gammopathy of undetermined signiﬁ cance. 
N Engl J Med. 2006; 355: 2765-70
8 Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of 
progression of light-chain monoclonal gammopathy of 
undetermined signiﬁ cance: a retrospective population-based cohort 
study. Lancet 2010; 375: 1721–28.
9 Merlini G, Palladini G. Diﬀ erential diagnosis of monoclonal 
gammopathy of undetermined signiﬁ cance. 
Hematology (Am Soc Hematol Educ Program) 2012; 2012: 595–603.
10 International Myeloma Working Group. Criteria for the 
classiﬁ cation of monoclonal gammopathies, multiple myeloma and 
related disorders: a report of the International Myeloma Working 
Group. Br J Haematol 2003; 121: 749–57.
11 Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk 
stratiﬁ cation and response assessment of multiple myeloma. 
Leukemia 2009; 23: 3–9.
12 Kyle RA, Larson DR, Therneau TM, et al. Clinical course of light-
chain smouldering multiple myeloma (idiopathic Bence Jones 
proteinuria): a retrospective study. Lancet Haematol 2014; 1: e28–36.
13 Dimopoulos MA, Kiamouris C, Moulopoulos LA. Solitary 
plasmacytoma of bone and extramedullary plasmacytoma. 
Hematol Oncol Clin North Am 1999; 13: 1249–57.
14 Hill QA, Rawstron AC, de Tute RM, Owen RG. Outcome prediction 
in solitary plasmacytoma of bone: a risk stratiﬁ cation model 
utilizing bone marrow ﬂ ow cytometry and light-chain analysis. 
Blood 2014; 124: 1296–99.
15 Paiva B, Chandia M, Vidriales MB, et al. Multiparameter ﬂ ow 
cytometry for staging of solitary bone plasmacytoma: new criteria for 
risk of progression to myeloma. Blood 2014; 124: 1300–03.
16 Warsame R, Gertz MA, Lacy MQ, et al. Trends and outcomes of 
modern staging of solitary plasmacytoma of bone. Am J Hematol 
2012; 87: 647–51.
17 Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: 
deﬁ nitions and long-term outcome. Blood 2003; 101: 2496–506.
18 Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of 
undetermined signiﬁ cance, Waldenström macroglobulinemia, AL 
amyloidosis, and related plasma cell disorders: diagnosis and 
treatment. Mayo Clin Proc 2006; 81: 693–703.
19 Dispenzieri A. POEMS syndrome. Blood Rev 2007; 21: 285–99.
20 Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 
IgM monoclonal gammopathy of undetermined signiﬁ cance. Blood 
2003; 102: 3759–64.
21 Kyle RA, Durie BGM, Rajkumar SV, et al, and the International 
Myeloma Working Group. Monoclonal gammopathy of 
undetermined signiﬁ cance (MGUS) and smoldering 
(asymptomatic) multiple myeloma: IMWG consensus perspectives 
risk factors for progression and guidelines for monitoring and 
management. Leukemia 2010; 24: 1121–27.
22 Landgren O. Monoclonal gammopathy of undetermined 
signiﬁ cance and smoldering multiple myeloma: biological 
insights and early treatment strategies. 
Hematology (Am Soc Hematol Educ Program) 2013; 2013: 478–87.
23 Schuster SR, Rajkumar SV, Dispenzieri A, et al. IgM multiple 
myeloma: disease deﬁ nition, prognosis, and diﬀ erentiation from 
Waldenstrom’s macroglobulinemia. Am J Hematol 2010; 
85: 853–55.
24 Turesson I, Kovalchik SA, Pfeiﬀ er RM, et al. Monoclonal 
gammopathy of undetermined signiﬁ cance and risk of lymphoid 
and myeloid malignancies: 728 cases followed up to 30 years in 
Sweden. Blood 2014; 123: 338–45.
25 Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of 
prognosis in monoclonal gammopathy of undetermined 
signiﬁ cance. N Engl J Med 2002; 346: 564–69.
26 Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for 
malignant transformation in monoclonal gammopathy of 
undetermined signiﬁ cance and smoldering multiple myeloma. 
J Clin Oncol 2002; 20: 1625–34.
27 Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain 
ratio is an independent risk factor for progression in monoclonal 
gammopathy of undetermined signiﬁ cance. Blood 2005; 106: 812–17.
28 Pérez-Persona E, Vidriales MB, Mateo G, et al. New criteria to 
identify risk of progression in monoclonal gammopathy of 
uncertain signiﬁ cance and smoldering multiple myeloma based on 
multiparameter ﬂ ow cytometry analysis of bone marrow plasma 
cells. Blood 2007; 110: 2586–92.
29 Katzmann JA, Clark R, Kyle RA, et al. Suppression of uninvolved 
immunoglobulins deﬁ ned by heavy/light chain pair suppression is 
a risk factor for progression of MGUS. Leukemia 2013; 27: 208–12.
30 Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and 
prognosis of smoldering (asymptomatic) multiple myeloma. 
N Engl J Med 2007; 356: 2582–90.
31 Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for 
smoldering multiple myeloma: results from a prospective clinical 
study. Leuk Lymphoma 2013; 54: 2215–18.
32 Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk 
smoldering myeloma. N Engl J Med 2013; 369: 1762–63.
e547 www.thelancet.com/oncology   Vol 15   November 2014
Review
33 Rajkumar SV. Preventive strategies in monoclonal gammopathy of 
undetermined signiﬁ cance and smoldering multiple myeloma. 
Am J Hematol 2012; 87: 453–54.
34 Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: 
Redeﬁ ning myeloma. Nat Rev Clin Oncol 2012; 9: 494–96.
35 Landgren O, Waxman AJ. Multiple myeloma precursor disease. 
JAMA 2010; 304: 2397–404.
36 Dimopoulos M, Kyle R, Fermand JP, et al, and the International 
Myeloma Workshop Consensus Panel 3. Consensus 
recommendations for standard investigative workup: report of the 
International Myeloma Workshop Consensus Panel 3. Blood 2011; 
117: 4701–05.
37 Rajkumar SV, Harousseau JL, Durie B, et al, and the International 
Myeloma Workshop Consensus Panel 1. Consensus 
recommendations for the uniform reporting of clinical trials: report 
of the International Myeloma Workshop Consensus Panel 1. Blood 
2011; 117: 4691–95.
38 Mateos M-V, Hernández M-T, Giraldo P, et al. Lenalidomide plus 
dexamethasone for high-risk smoldering multiple myeloma. 
N Engl J Med 2013; 369: 438–47.
39 Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering 
multiple myeloma requiring treatment: time for a new deﬁ nition? 
Blood 2013; 122: 4172–81.
40 Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, 
Landgren O. Molecular and biologic markers of progression in 
monoclonal gammopathy of undetermined signiﬁ cance to multiple 
myeloma. Leuk Lymphoma 2010; 51: 2159–70.
41 Landgren O, Rajkumar SV. Development of early treatment 
strategies for high-risk myeloma precursor disease in the future. 
Semin Hematol 2011; 48: 66–72.
42 Landgren O. Multiple myeloma precursor disease: current clinical 
dilemma and future opportunities. Semin Hematol 2011; 48: 1–3.
43 Rajkumar SV. Prevention of progression in monoclonal 
gammopathy of undetermined signiﬁ cance. Clin Cancer Res 2009; 
15: 5606–08.
44 Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free 
light chain ratio is an independent risk factor for progression of 
smoldering (asymptomatic) multiple myeloma. Blood 2008; 
111: 785–89.
45 Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple 
myeloma. N Engl J Med 2011; 365: 474–75.
46 Richardson PG, Sonneveld P, Schuster MW, et al, and the 
Assessment of Proteasome Inhibition for Extending Remissions 
(APEX) Investigators. Bortezomib or high-dose dexamethasone for 
relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–98.
47 Dimopoulos M, Spencer A, Attal M, et al, and the Multiple 
Myeloma (010) Study Investigators. Lenalidomide plus 
dexamethasone for relapsed or refractory multiple myeloma. 
N Engl J Med 2007; 357: 2123–32.
48 Rajkumar SV, Jacobus S, Callander NS, et al, and the Eastern 
Cooperative Oncology Group. Lenalidomide plus high-dose 
dexamethasone versus lenalidomide plus low-dose dexamethasone 
as initial therapy for newly diagnosed multiple myeloma: an open-
label randomised controlled trial. Lancet Oncol 2010; 11: 29–37.
49 Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, 
and dexamethasone combination therapy in patients with newly 
diagnosed multiple myeloma. Blood 2010; 116: 679–86.
50 Jakubowiak AJ, Dytfeld D, Griﬃ  th KA, et al. A phase 1/2 study of 
carﬁ lzomib in combination with lenalidomide and low-dose 
dexamethasone as a frontline treatment for multiple myeloma. 
Blood 2012; 120: 1801–09.
51 Lacy MQ, Hayman SR, Gertz MA, et al. Pomalidomide (CC4047) 
plus low-dose dexamethasone as therapy for relapsed multiple 
myeloma. J Clin Oncol 2009; 27: 5008–14.
52 Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rödjer S, 
Westin J, and the Myeloma Group of Western Sweden. Initial 
versus deferred melphalan-prednisone therapy for asymptomatic 
multiple myeloma stage I--a randomized study. Eur J Haematol 
1993; 50: 95–102.
53 Riccardi A, Mora O, Tinelli C, et al, and the Cooperative Group of 
Study and Treatment of Multiple Myeloma. Long-term survival of 
stage I multiple myeloma given chemotherapy just after diagnosis 
or at progression of the disease: a multicentre randomized study. 
Br J Cancer 2000; 82: 1254–60.
54 Dimopoulos M, Terpos E, Comenzo RL, et al, and the IMWG. 
International myeloma working group consensus statement and 
guidelines regarding the current role of imaging techniques in the 
diagnosis and monitoring of multiple Myeloma. Leukemia 2009; 
23: 1545–56.
55 Hillengass J, Landgren O. Challenges and opportunities of novel 
imaging techniques in monoclonal plasma cell disorders: imaging 
“early myeloma”. Leuk Lymphoma 2013; 54: 1355–63.
56 Regelink JC, Minnema MC, Terpos E, et al. Comparison of modern 
and conventional imaging techniques in establishing multiple 
myeloma-related bone disease: a systematic review. Br J Haematol 
2013; 162: 50–61.
57 Kastritis E, Terpos E, Moulopoulos L, et al. Extensive bone marrow 
inﬁ ltration and abnormal free light chain ratio identiﬁ es patients 
with asymptomatic myeloma at high risk for progression to 
symptomatic disease. Leukemia 2013; 27: 947–53.
58 Waxman AJ, Mick R, Garfall AL, et al. Modeling the risk of 
progression in smoldering multiple myeloma. 
Proc Am Soc Clin Oncol 2014; 32: A8607 (abstr).
59 Johnsen HE, Bøgsted M, Klausen TW, et al, and the Nordic 
Myeloma Study (NMSG), and the Myeloma Stem Cell Network 
(MSCNET). Multiparametric ﬂ ow cytometry proﬁ ling of neoplastic 
plasma cells in multiple myeloma. Cytometry B Clin Cytom 2010; 
78: 338–47.
60 Rajkumar SV, Fonseca R, Dispenzieri A, et al. Methods for 
estimation of bone marrow plasma cell involvement in myeloma: 
predictive value for response and survival in patients undergoing 
autologous stem cell transplantation. Am J Hematol 2001; 
68: 269–75.
61 Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, 
automated immunoassay for immunoglobulin free light chains in 
serum and urine. Clin Chem 2001; 47: 673–80.
62 Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference 
intervals and diagnostic ranges for free kappa and free lambda 
immunoglobulin light chains: relative sensitivity for detection of 
monoclonal light chains. Clin Chem 2002; 48: 1437–44.
63 Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. 
Serum test for assessment of patients with Bence Jones myeloma. 
Lancet 2003; 361: 489–91.
64 Dispenzieri A, Kyle R, Merlini G, et al, and the International 
Myeloma Working Group. International Myeloma Working Group 
guidelines for serum-free light chain analysis in multiple myeloma 
and related disorders. Leukemia 2009; 23: 215–24.
65 Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al. Prognostic value 
of serum free light chain ratio at diagnosis in multiple myeloma. 
Br J Haematol 2007; 137: 240–43.
66 Snozek CLH, Katzmann JA, Kyle RA, et al. Prognostic value of the 
serum free light chain ratio in newly diagnosed myeloma: proposed 
incorporation into the international staging system. Leukemia 2008; 
22: 1933–37.
67 Dingli D, Kyle RA, Rajkumar SV, et al. Immunoglobulin free light 
chains and solitary plasmacytoma of bone. Blood 2006; 108: 1979–83.
68 Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, 
Rajkumar SV. Serum free light chain ratio as a biomarker for high-
risk smoldering multiple myeloma. Leukemia 2013; 27: 941–46.
69 Moulopoulos LA, Dimopoulos MA, Smith TL, et al. Prognostic 
signiﬁ cance of magnetic resonance imaging in patients with 
asymptomatic multiple myeloma. J Clin Oncol 1995; 13: 251–56.
70 Mariette X, Zagdanski AM, Guermazi A, et al. Prognostic value of 
vertebral lesions detected by magnetic resonance imaging in 
patients with stage I multiple myeloma. Br J Haematol 1999; 
104: 723–29.
71 Wang M, Alexanian R, Delasalle K, Weber D. Abnormal MRI of 
spine is the dominant risk factor for early progression of 
asymptomatic multiple myeloma. Blood 2003; 102: 687a.
72 Hillengass J, Fechtner K, Weber MA, et al. Prognostic signiﬁ cance 
of focal lesions in whole-body magnetic resonance imaging in 
patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 
28: 1606–10.
73 Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, 
Dimopoulos MA. The prognostic importance of the presence of 
more than one focal lesion in spine MRI of patients with 
asymptomatic (smoldering) multiple myeloma. Leukemia 2014; 
published online July 31. DOI:10.1038/leu.2014.230.
www.thelancet.com/oncology   Vol 15   November 2014 e548
Review
74 Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, 
Alexanian R. Risk of disease progression in asymptomatic multiple 
myeloma. Am J Med 1993; 94: 57–61.
75 Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, 
Smith T, Alexanian R. Prognostic features of asymptomatic 
multiple myeloma. Br J Haematol 1997; 97: 810–14.
76 Merz M, Hielscher T, Wagner B, et al. Predictive value of 
longitudinal whole-body magnetic resonance imaging in patients 
with smoldering multiple myeloma. Leukemia 2014; 28: 1902–08.
77 Zamagni E, Cavo M. The role of imaging techniques in the 
management of multiple myeloma. Br J Haematol 2012; 
159: 499–513.
78 Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 
18F-ﬂ uorodeoxyglucose positron emission tomography-computed 
tomography, magnetic resonance imaging and whole-body planar 
radiographs in the assessment of bone disease in newly diagnosed 
multiple myeloma. Haematologica 2007; 92: 50–55.
79 Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging 
in multiple myeloma: diagnostic and clinical implications. 
J Clin Oncol 2007; 25: 1121–28.
80 Bartel TB, Haessler J, Brown TL, et al. F18-ﬂ uorodeoxyglucose 
positron emission tomography in the context of other imaging 
techniques and prognostic factors in multiple myeloma. Blood 2009; 
114: 2068–76.
81 Waheed S, Mitchell A, Usmani S, et al. Standard and novel imaging 
methods for multiple myeloma: correlates with prognostic 
laboratory variables including gene expression proﬁ ling data. 
Haematologica 2013; 98: 71–78.
82 Leung N, Bridoux F, Hutchison CA, et al, and the International 
Kidney and Monoclonal Gammopathy Research Group. Monoclonal 
gammopathy of renal signiﬁ cance: when MGUS is no longer 
undetermined or insigniﬁ cant. Blood 2012; 120: 4292–95.
83 Hutchison CA, Batuman V, Behrens J, et al, and the International 
Kidney and Monoclonal Gammopathy Research Group. The 
pathogenesis and diagnosis of acute kidney injury in multiple 
myeloma. Nat Rev Nephrol 2012; 8: 43–51.
84 Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. 
Diagnostic performance of quantitative kappa and lambda free light 
chain assays in clinical practice. Clin Chem 2005; 51: 878–81.
85 Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with 
newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 
78: 21–33.
86 Dimopoulos MA, Pouli A, Anagnostopoulos A, et al. Macrofocal 
multiple myeloma in young patients: a distinct entity with favorable 
prognosis. Leuk Lymphoma 2006; 47: 1553–56.
87 Dispenzieri A. How I treat POEMS syndrome. Blood 2012; 
119: 5650–58.
88 Sethi S, Rajkumar SV. Monoclonal gammopathy-associated 
proliferative glomerulonephritis. Mayo Clin Proc 2013; 88: 1284–93.
89 Kourelis TV, Kumar SK, Gertz MA, et al. Coexistent multiple 
myeloma or increased bone marrow plasma cells deﬁ ne equally 
high-risk populations in patients with immunoglobulin light chain 
amyloidosis. J Clin Oncol 2013; 31: 4319–24.
90 Nobile-Orazio E. Neuropathy and monoclonal gammopathy. 
Handb Clin Neurol 2013; 115: 443–59.
91 Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-
stratiﬁ cation, and management. Am J Hematol 2014; 89: 214–23.
92 Lacy MQ, Gertz MA, Hanson CA, Inwards DJ, Kyle RA. Multiple 
myeloma associated with diﬀ use osteosclerotic bone lesions: a 
clinical entity distinct from osteosclerotic myeloma (POEMS 
syndrome). Am J Hematol 1997; 56: 288–93.
93 Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral 
blood circulating plasma cells as a speciﬁ c risk factor for 
progression of smoldering multiple myeloma. Leukemia 2013; 
27: 680–85.
94 Pérez-Persona E, Mateo G, García-Sanz R, et al. Risk of progression 
in smouldering myeloma and monoclonal gammopathies of 
unknown signiﬁ cance: comparative analysis of the evolution of 
monoclonal component and multiparameter ﬂ ow cytometry of bone 
marrow plasma cells. Br J Haematol 2010; 148: 110–14.
95 Rawstron AC, Orfao A, Beksac M, et al, and the European Myeloma 
Network. Report of the European Myeloma Network on 
multiparametric ﬂ ow cytometry in multiple myeloma and related 
disorders. Haematologica 2008; 93: 431–38.
96 Rosiñol L, Bladé J, Esteve J, et al. Smoldering multiple myeloma: 
natural history and recognition of an evolving type. Br J Haematol 
2003; 123: 631–36.
97 Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary 
molecular cytogenetic abnormalities and risk of progression in 
smoldering multiple myeloma. Leukemia 2013; 27: 1738–44.
98 Neben K, Jauch A, Hielscher T, et al. Progression in smoldering 
myeloma is independently determined by the chromosomal 
abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor 
load. J Clin Oncol 2013; 31: 4325–32.
99 Madan S, Kyle RA, Greipp PR. Plasma cell labeling index in the 
evaluation of smoldering (asymptomatic) multiple myeloma. 
Mayo Clin Proc 2010; 85: 300.
100 Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genomic, and 
imaging predictors of myeloma progression from asymptomatic 
monoclonal gammopathies (SWOG S0120). Blood 2014; 123: 78–85.
